Notice of Results and Investor Presentation

Aptamer Group PLC

17 October 2024

 

17 October 2024

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Notice of Results and Investor Presentation

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its full year results for the year ended 30 June 2024 on Tuesday, 22 October 2024.

The Company is pleased to announce that Dr Arron Tolley, Chief Executive Officer and Andrew Rapson, Chief Financial Officer will provide a live presentation relating to the full year results via Investor Meet Company on Tuesday, 22 October 2024 at 2:00 pm GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Aptamer Group plc via: 

https://www.investormeetcompany.com/aptamer-group-plc/register-investor

Investors who already follow Aptamer Group plc on the Investor Meet Company platform will automatically be invited.

- Ends -

For further information, please contact: 

Aptamer Group plc   Arron Tolley	[phone]
SPARK Advisory Partners Limited - Nominated Adviser     Andrew Emmott / Adam Dawes	[phone]
Turner Pope Investments (TPI) Limited - Broker     James Pope / Andrew Thacker	[phone]
Northstar Communications Limited - Investor Relations Sarah Hollins	[phone]

About Aptamer Group plc 

Aptamer Group develops custom affinity binders through its proprietary Optimer^® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers.  Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.  

Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.  

 

END